Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Infection
68%
Antibiotics
65%
Prospective Cohort Study
37%
Mycobacterium abscessus
37%
Sepsis
31%
Antiinfective Agent
30%
Linezolid
28%
Chronic Kidney Failure
25%
Hepatitis C Virus
25%
Delamanid
25%
Amikacin
24%
Drug-Drug Interaction
24%
Antiviral Drug
23%
Imipenem
22%
Community Acquired Pneumonia
18%
Cohort Study
18%
Mycobacterium Tuberculosis
17%
Bedaquiline
17%
Monotherapy
16%
Clofazimine
16%
Drug Development
16%
Pretomanid
15%
Ethambutol
15%
Antimicrobial Resistance
15%
Sodium Valproate
15%
Mortality Rate
14%
Drug Resistant Tuberculosis
14%
Diseases
14%
Human Immunodeficiency Virus Infection
13%
Cardiovascular Disease
13%
Immunocompromised Patient
12%
Virus Hepatitis
12%
Monoclonal Antibody
12%
SARS Coronavirus
12%
Malignant Neoplasm
12%
Vaccinium Myrtillus Anthocyanoside
12%
Bacterin
12%
Cefalexin
12%
Multidrug-Resistant Gram-Negative Bacteria
12%
Drug Interaction
12%
Staphylococcal Bacteremia
12%
Osteomyelitis
12%
Gram Positive Infection
12%
Mycobacterium marinum
12%
Drug
12%
Rifamycin
12%
Predictive Modeling
12%
Dolutegravir
12%
Device Infection
12%
Medicine and Dentistry
Human Immunodeficiency Virus
97%
Antiretroviral Therapy
42%
Prospective Cohort Study
37%
COVID-19
31%
Antibiotics
31%
Infection
27%
Immunocompromised Patient
25%
Antibiotic Therapy
25%
Noninferiority Trial
25%
Hepatitis C Virus
25%
Chronic Kidney Disease
25%
Severe Acute Respiratory Syndrome Coronavirus 2
17%
Antiviral Drug
17%
Diseases
17%
Monotherapy
16%
Glomerular Filtration Rate
15%
Human Immunodeficiency Virus Infection
14%
Omicron Coronavirus Variant
14%
Cohort Analysis
13%
Observational Study
13%
Cardiovascular Disease
13%
Imipenem
13%
Monoclonal Antibody Therapy
12%
Treatment Duration
12%
Malignant Neoplasm
12%
Sepsis
12%
Thrombosis
12%
Dolutegravir
12%
Intensive Care Unit
12%
Left Ventricular Assist Device
12%
Vaccinium Myrtillus Anthocyanoside
12%
Device Infection
12%
Endocarditis
12%
Gram Positive Infection
12%
Hepatitis Virus
12%
Osteomyelitis
12%
Fibrinolysis
12%
Drug Interaction
12%
Multidrug-Resistant Gram-Negative Bacteria
12%
Sex Difference
12%
Cardiovascular System
12%
Schistosoma
12%
Spinal Cord Disease
12%
Staphylococcal Bacteremia
12%
Mycobacterium abscessus
12%
Drug Activity
12%
Doravirine
12%
Community-Acquired Pneumonia
12%
Adjuvant Therapy
12%
Antiviral Therapy
11%